Survodutide Phase 3 data explained: what the SYNCHRONIZE trials found

• Survodutide is a glucagon/GLP-1 dual agonist (BI 456906). It is investigational and not FDA-approved.
• SYNCHRONIZE-1 (76 weeks, obesity without T2D): up to 16.6% average weight loss vs. 3.2% in the placebo group (p<0.0001).
• SYNCHRONIZE-MASLD (48 weeks, obesity + MASLD): up to 84.2% of participants achieved ≥30% relative liver fat reduction vs. 24.3% placebo (p<0.0001).
• GI side effects were common; 19% of SYNCHRONIZE-1 participants discontinued due to GI events vs. 2.9% on placebo.
• No head-to-head trials compare survodutide to approved GLP-1s. Direct comparisons cannot be made from these results.

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work primarily by activating GLP-1 receptors in the gut and brain, reducing appetite and slowing gastric emptying.

Survodutide adds glucagon receptor activation to that mechanism. Glucagon is best known for raising blood sugar — but glucagon receptor activation also increases energy expenditure and promotes fat metabolism in the liver. The rationale behind dual agonism is that combining these pathways might produce greater metabolic effects, particularly on liver fat, than GLP-1 activation alone.

MALD stands for metabolic dysfunction-associated steatotic liver disease — excess fat buildup in the liver, often linked to obesity. Up to three in four people with obesity have some degree of MASLD. In a subset of cases it can progress to MASH (metabolic dysfunction-associated steatohepatitis), which involves active liver inflammation and damage.

SYNCHRONIZE-1 enrolled adults with obesity or overweight without type 2 diabetes and ran for 76 weeks. It tested multiple doses of survodutide against placebo.

Key results from the Boehringer Ingelheim press release and the NEJM publication:

• Average weight loss: up to 16.6% from baseline (efficacy estimand) vs. 3.2% for placebo (p<0.0001).
• Visceral fat: up to 34.0% relative reduction from baseline in a MRI substudy.
• Lean mass: lean mass accounted for no more than 10.8% of total tissue change at the highest dose — meaning weight loss was predominantly fat mass.
• Liver fat: up to 63.1% relative reduction from baseline in a pre-specified substudy analysis.
• GI events (nausea, vomiting, diarrhea, constipation) were the most common adverse events; 19% of survodutide participants discontinued due to GI adverse events vs. 2.9% on placebo. No new safety signals were identified.

SYNCHRONIZE-MASLD enrolled adults with overweight or obesity who had MASLD with evidence of inflammation or fibrosis — including both those with and without type 2 diabetes. The trial ran for 48 weeks.

Key results:

• Co-primary endpoint 1: Up to 84.2% of participants achieved ≥30% relative liver fat reduction vs. 24.3% in the placebo group (p<0.0001).
• Co-primary endpoint 2: Relative body weight reduction of up to 12.2% vs. 1.0% in placebo (p<0.0001).
• Secondary endpoint: Up to 61.0% of participants reached liver fat normalization (liver fat content <5%) vs. 5.7% in placebo.
• Positive trends were observed in ALT (alanine transaminase) levels, a marker of liver inflammation.

These results were published in Nature Medicine and presented at ADA 2026.

This is an important question — and the data don't answer it.

There are no head-to-head trials comparing survodutide to semaglutide or tirzepatide. SYNCHRONIZE-1's 16.6% weight loss result sits in a range broadly comparable to semaglutide trials and somewhat below what has been observed with the highest doses of tirzepatide — but comparing across trials is unreliable. Study populations, enrollment criteria, trial designs, and endpoint definitions differ.

The liver fat results from SYNCHRONIZE-MASLD are notable, but cannot be compared directly to liver fat outcomes in semaglutide or tirzepatide trials without a head-to-head design.

• No comparative efficacy data. Whether survodutide performs better or differently than approved options is unknown.
• Longer-term outcomes. Cardiovascular outcomes, kidney outcomes, and safety data beyond 76 weeks have not been established in Phase 3.
• Histologic liver outcomes. SYNCHRONIZE-MASLD measured liver fat (by MRI) and body weight — not biopsy-confirmed resolution of MASH or fibrosis regression, which are typically required for liver disease drug approvals.
• Regulatory timeline. Boehringer Ingelheim has not announced an NDA submission date or projected FDA review timeline. Approval is not imminent, and no timeline should be assumed from publication of Phase 3 data.

Survodutide would require a New Drug Application (NDA) to the FDA and a full regulatory review before it could be prescribed. Publishing Phase 3 results in NEJM and Nature Medicine is one step in building that dossier — not an approval event.

If you have MASLD alongside obesity, established approaches — including lifestyle changes and FDA-approved medications — are available now. Whether you might qualify for a clinical trial of survodutide or a similar agent is worth asking your clinician.

• Do I have MASLD, and how is it being monitored over time?
• What are the current approved options for my situation — for both weight and liver health?
• Am I a candidate for clinical trials in this area?
• What liver markers should we track, and how often?

• Liver function tests (ALT, AST) — standard blood tests your clinician can order
• Any symptoms potentially related to liver disease: persistent fatigue, abdominal discomfort, yellowing of skin or eyes
• Weight and body composition over time with your current treatment plan

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Boehringer Ingelheim press release — SYNCHRONIZE-1 and SYNCHRONIZE-MASLD: boehringer-ingelheim.com
• NEJM — SYNCHRONIZE-1: nejm.org
• Nature Medicine — SYNCHRONIZE-MASLD: nature.com
• ClinicalTrials.gov NCT06066515: clinicaltrials.gov